After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Ultragenyx Pharmaceutical Inc is $3.54B. A total of 0.69 million shares were traded on the day, compared to an average of 1.02M shares.
In the most recent transaction, Sanders Corazon (Corsee) D. sold 2,405 shares of RARE for 37.39 per share on Jun 20 ’25. After the transaction, the Director now owns 15,344 company shares. In a previous transaction on Jun 20 ’25, CORAZON D. SANDERS bought 2,405 shares at 37.39 per share.
Among the insiders who sold shares, Crombez Eric disposed of 520 shares on May 05 ’25 at a per-share price of $39.24. This resulted in the EVP and Chief Medical Officer holding 71,530 shares of RARE after the transaction. In another insider transaction, Crombez Eric sold 242 shares at $35.11 per share on Apr 21 ’25. Company shares held by the EVP and Chief Medical Officer now total 71,680.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, RARE has a high of $60.37 and a low of $29.59.
As of this writing, RARE has an earnings estimate of -$1.33 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of -$1.11 per share and a lower estimate of -$1.41.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RARE’s latest balance sheet shows that the firm has $740.20M in Cash & Short Term Investments as of fiscal 2021. There were $41.97M in debt and $181.37M in liabilities at the time. Its Book Value Per Share was $1.54, while its Total Shareholder’s Equity was $922.56M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RARE is Buy with a score of 4.85.
